GeneDx Holdings Corp
For the period ended Dec 31, 2024. Filed Feb 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 20, 2025
WGS$65.72+5.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $85,212 | $99,681 |
| Marketable securities | 55,973 | 30,467 |
| Accounts receivable | 37,426 | 32,371 |
| Due from related parties | 203 | 445 |
| Inventory, net | 10,650 | 8,777 |
| Prepaid expenses and other current assets | 8,504 | 10,598 |
| Total current assets | 197,968 | 182,339 |
| Operating lease right-of-use assets | 25,613 | 26,900 |
| Property and equipment, net | 32,893 | 32,479 |
| Intangible assets, net | 158,600 | 172,625 |
| Other assets | 4,306 | 4,413 |
| Total assets | $419,380 | $418,756 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $30,044 | $37,456 |
| Due to related parties | 1,607 | 1,379 |
| Short-term lease liabilities | 3,336 | 3,647 |
| Other current liabilities | 19,830 | 16,336 |
| Total current liabilities | 54,817 | 58,818 |
| Long-term debt, net of current portion | 51,913 | 52,688 |
| Long-term lease liabilities | 60,919 | 62,938 |
| Other liabilities | 5,519 | 14,735 |
| Deferred taxes | 965 | 1,560 |
| Total liabilities | 174,133 | 190,739 |
| Purchase commitments and contingencies (Note 10) | ||
| Stockholders’ Equity: | ||
| Preferred Stock, $0.0001 par value: 1,000,000 shares authorized, 0 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | — | — |
| Class A common stock, $0.0001 par value: 1,000,000,000 shares authorized, 28,016,545 and 25,978,863 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 2 | 2 |
| Additional paid-in capital | 1,596,889 | 1,527,778 |
| Accumulated deficit | (1,352,474) | (1,300,188) |
| Accumulated other comprehensive income | 830 | 425 |
| Total stockholders’ equity | 245,247 | 228,017 |
| Total liabilities and stockholders’ equity | $419,380 | $418,756 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.